0
0
December 7, 2025
ATLANTA — In a landmark decision that overturns more than three decades of public health policy, a U.S. vaccine advisory committee voted Friday to eliminate the recommendation that all newborns receive the Hepatitis B vaccine shortly after birth.
The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted 8-3 on December 5 to scrap the universal birth dose for infants whose mothers test negative for the virus. Instead, the panel recommended a “shared clinical decision-making” approach, advising parents to consult with healthcare providers to determine if and when to administer the vaccine, with the first dose suggested no sooner than two months of age.
The move marks a significant victory for Health and Human Services Secretary Robert F. Kennedy Jr., who appointed the current committee members earlier this year after dismissing the previous roster. While the committee cited a desire to align U.S. policy with other developed nations and prioritize parental choice, the decision has drawn sharp rebuke from major medical organizations and infectious disease experts who warn it could reverse historic gains in preventing liver disease.
The New Guidelines
Since 1991, the CDC has recommended that every infant receive the first dose of the Hepatitis B vaccine within 24 hours of birth to prevent vertical transmission (from mother to baby) and early childhood infection. Under the new guidance:
-
Universal Birth Dose Scrapped: The automatic birth dose is no longer recommended for the majority of infants.
-
Targeted Approach: The birth dose remains recommended only for infants born to mothers who test positive for Hepatitis B or whose infection status is unknown.
-
Delayed Schedule: For infants of mothers who test negative, the committee suggests starting the vaccine series at two months, rather than at birth.
-
Antibody Testing: The panel also voted to recommend that parents consult doctors about testing children for antibody levels before subsequent doses—a practice critics note is not standard for routine immunization.
Committee’s Rationale: Choice and International Norms
The reconstituted ACIP panel argued that the universal recommendation was outdated given the low prevalence of Hepatitis B in the United States compared to the early 1990s. Committee members pointed to countries like Denmark and Finland, which do not routinely vaccinate all newborns, as evidence that the U.S. was an outlier.
“People should be very, very suspicious when people tell them that something is safe, especially a vaccine,” said committee member Retsef Levi, a mathematician at the Massachusetts Institute of Technology, during the contentious two-day meeting. Levi and other members emphasized that for mothers who screen negative, the risk to the infant is negligible, making the birth dose unnecessary medicine.
The decision aligns with a broader push by the current administration to review health guidelines. Following the vote, the White House issued a statement supporting the move to “align child immunization recommendations with best practices from peer developed countries.”
Medical Establishment Sounds the Alarm
The decision has triggered an immediate and forceful response from the medical community. Organizations including the American Academy of Pediatrics (AAP) and the American Medical Association (AMA) issued statements decrying the move as dangerous and scientifically unsound.
Public health experts argue that the birth dose serves as a critical “safety net.” While maternal screening is standard, tests can yield false negatives, and mothers’ medical histories are not always accessible at delivery.
“The vaccine is incredibly safe and has had a historic positive impact on public health since its inception,” said Dr. Richard Rupp, a professor of pediatrics at the University of Texas Medical Branch. “Rolling back the initiative to protect all children will almost certainly lead to an increase in Hepatitis B cases nationwide.”
Data from the CDC indicates that since the introduction of the universal birth dose in 1991, acute Hepatitis B infections in children and adolescents have dropped by approximately 99%.
Dr. Tom Frieden, former CDC director and CEO of Resolve to Save Lives, warned of the long-term consequences: “The ACIP recommendation to end the universal birth dose… puts millions of American children at greater risk of liver damage, cancer, and early death.”
The Stakes for Public Health
Hepatitis B is a viral infection that attacks the liver. While adults often recover, the virus is particularly devastating for infants. According to the World Health Organization (WHO), approximately 90% of infants infected during their first year of life develop chronic Hepatitis B, which can lead to cirrhosis and liver cancer later in life.
“We will see more children and adolescents and adults infected with Hepatitis B,” warned Joseph Hibbeln, one of the three committee members who voted against the change.
Critics also noted that shifting to “shared clinical decision-making” could exacerbate health disparities. Families with less consistent access to prenatal care or healthcare providers may be more likely to miss the window for vaccination or maternal screening, leaving their infants vulnerable.
What This Means for Parents
For parents welcoming children in 2026, the standard of care in hospitals is set to change.
-
Hospital Protocols: Hospitals will likely update their standing orders to stop automatically offering the vaccine to newborns of negative mothers.
-
Insurance Coverage: While major insurers have stated they will continue to cover the shot, the change in recommendation could eventually impact coverage mandates, which often rely on ACIP guidelines.
-
Doctor Conversations: Pediatricians are expected to have more in-depth conversations with parents about the risks and benefits. The AAP has stated it will continue to recommend the birth dose, potentially creating a conflict between federal guidelines and pediatric best practices.
The recommendations now head to the CDC Director for final approval, typically a formality, though the acting director has signaled support for the committee’s new direction.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
-
Advisory Committee on Immunization Practices (ACIP). (2025, December 5). Meeting Proceedings: Vote on Hepatitis B Vaccine Recommendations. Centers for Disease Control and Prevention.
